Over the past decade, immunotherapy has become a cornerstone in enhancing survival outcomes for cancer patients. Recent studies, including our own, have provided compelling evidence that tertiary lymphoid structures (TLS) are pivotal in orchestrating anti-tumor immune responses in melanoma. These specialized immune niches are critical determinants of immunotherapy efficacy, influencing patient outcomes. We are actively trying to understand the functional role and clinical significance of TLS in cancer. 

Group Members

Martin Lauss
Katja Harbst
Bengt Phung
Kamila Kaminska
Florian Jeanneret
Jacob Karlström
Cecilia Wahlström
Zacharias Ringstedt